Monday, January 18, 2021

LATEST ARTICLES

Innovative diabetes management solution (Accu-Chek SugarView app) announced by Roche

Dec 10, 2019: Roche announced that it has obtained the CE Mark for its Accu-Chek SugarView app, innovative diabetes management solution in...

Daiichi Sankyo Initiates Pivotal Phase 2 Trial in Japan with Valemetostat to treat patients with adult T-cell leukemia-lymphoma

Dec 10, 2019: Daiichi Sankyo Company, Limited announced  that the first patient has been dosed in a pivotal phase 2 study in...

Healx collaborates with Boehringer Ingelheim to discover new treatment approaches for rare neurological diseases

Dec 09, 2019: Healx the AI-powered biotechnology company, announces that it has entered into an agreement with Boehringer Ingelheim to identify indications...

GenesisCare launched UK’s first MRIdian radiotherapy machine: a new radiotherapy treatment to reduce treatment time

Dec. 10, 2019: Cancer patients can begin from today potential access to the UK’s first MRIdian machine, a new radiotherapy treatment to...

FDA OKs to Navigen for its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor

Dec. 10, 2019: Navigen, Inc. announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug application ("IND")...

Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA for the treatment of BCG-unresponsive non-muscle invasive bladder cancer

Dec  09, 2019: Sesen Bio announced that on December 6, 2019, the Company initiated the submission of its Biologics License Application (BLA) for...

First and only ingestible event marker (the ID-Cap® System)approved by U.S. FDA

Dec 09, 2019: EtectRx® Inc. announced U.S. Food and Drug Administration (FDA) clearance of its breakthrough patented ingestible event marker, the ID-Cap® System...

Moberg Pharma meets primary endpoint for MOB-015 (topical terbinafine) in a phase 3 study for the treatment of Onychomycosis

Dec 9, 2019: Moberg Pharma announces that MOB-015 (topical terbinafine) met the primary endpoint and also key secondary endpoints in the North...

U.S. FDA approved Fast Track designation for Equillium’s itolizumab (EQUALISE Phase 1b study )for the treatment of lupus nephritis

Dec. 09, 2019 : The U.S. Food and Drug Administration (FDA) approved Fast Track designation for Equillium’s itolizumab for the treatment of lupus...

Important data points in Protocol for CRFs Creation (CDM Prospective):

Reading of whole protocol is quite important and indispensable act but by keeping following points in mind, one can read protocol with...

Parts of a clinical trial protocol and Clinical Data Management (CDM) prospective to review

This blog talks about Protocol parts and key information needed for any Data Manager to design CRF. Protocols are quite specific to studies but...

Only treatment approved in the US for relapsed or refractory hairy cell leukemia Approved by FDA at ASH 2019

Dec. 08, 2019: Innate Pharma shared new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox-tdfk) at the 61st...

Other

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Covaxin: Everything that you should know

Covaxin is an investigational vaccine candidate for COVID19. It is in Phase III clinical trial as of today (20-Dec-2020). It is being...

Interview with Kashish Gupta: NIPER 2020, AIR-36

NIPER is a well renowned institute that offers Master's degree after qualifying GPAT (Graduate Pharmacy Aptitude Test) and NIPER entrance test. NIPER...